Spyre Therapeutics, Inc. stock is down -21.08% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 February’s closed higher than January.
Aeglea BioTherapeutics, Inc. designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pezilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial. It also develops AGLE-177, a polyethylene glycol modified, which is in clinical trials for homocystinuria.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!